PODular cleanroom configurations have been selected to improve flexibility in pharmaceutical formulation for both sterile and oral solid-dosage products
Merck, known as MSD outside the US and Canada, has broken ground on its new facility. The new building will be called the Formulation Laboratory, Experimental (FLEx) Center and has begun construction in New Jersey, US.
Earlier this year, G-CON Manufacturing was selected to provide G-CON’s POD technology for the new FLEx Center based on the PODs’ flexibility, speed and ability to be repurposed.
The new build will be a high-tech facility that will make manufacturing more agile and sustainable using PODular cleanroom configurations.
The use of the configuration is in order to provide improved flexibility in pharmaceutical formulation and process development for both sterile and oral solid-dosage products.
Artist rendering of the finished facility
The facility is scheduled to open in 2021.
“Having a leader like Merck select our G-CON PODs for their cleanroom infrastructure really validates our product in the marketplace. It is a privilege to work with the Merck team in fulfilling the vision for ultimate flexibility in manufacturing,” said Maik Jornitz, CEO of G-CON.
Allen C Templeton, VP of Pharmaceutical Sciences at Merck Research Laboratories, said: “The groundbreaking of the FLEx centre at our Rahway, NJ site commences our journey to establish a world-class pharmaceutical processing facility that is reconfigurable with the evolving and dynamic technology needs of our pipeline.”
“We are pleased to collaborate with G-CON, along with other key construction and equipment providers, to enable our vision to create more effective means to develop and manufacture our products,” Templeton added.